GRCE — Grace Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1444192 ·
Last close
$1.72
Market Cap
$36.18M
52W High
$5.18
52W Low
$1.64
ADV30
105,779
Next earnings
—
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -2,292,000 -2,131,000 57,698,000 21,311,000 2,218,000
Jun 2026 0 — -2,384,000 -15,790,000 50,073,000 13,756,000 1,862,000
Mar 2026 0 — -3,010,000 -1,178,000 66,654,000 16,977,000 2,758,000
Dec 2025 0 — -2,449,000 -2,315,000 68,488,000 18,672,000 3,596,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,930,000
Investing CF
$0
Financing CF
$13,379,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.22
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-246,401,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-10,135,000
Pretax Income TTM
$-23,122,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 0 -11,077,000 -7,793,000 66,654,000 2,758,000 63,896,000 -8,869,000
Mar 2025 0 -16,679,000 -9,568,000 71,993,000 5,383,000 66,610,000 -14,904,000
Mar 2024 0 -11,367,000 -12,853,000 73,300,000 11,557,000 61,743,000 -12,333,000
Mar 2023 0 -18,247,000 -42,429,000 79,123,000 11,168,000 67,955,000 -15,913,000
Mar 2022 — — — — — — —

TTM Snapshot

Revenues TTM
$621,000
NetIncome TTM
$-20,221,000
OpCashFlow TTM
—
Assets (Latest)
$50,073,000
Forward EPS
$-0.42

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.73 · call volume: 1 · put volume: 362
Expected Move to 2027-05-21: ±$1.17 (67.92%) — implied range $0.56 – $2.91 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SER Serina Therapeutics, Inc. $36.27M $1.37 —
CNTB Connect Biopharma Holdings Ltd $36.45M $0.58 —
VERU VERU INC. $36.49M $2.14 —
BMEA Biomea Fusion, Inc. $35.47M $0.49 —
OSTX OS Therapies Inc $34.86M $0.74 —

News headlines (Yahoo Finance, 1h cache)

Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update
2026-11-12 13:00 · Yahoo
Grace: Fiscal Q2 Earnings Snapshot
2026-11-12 12:58 · Yahoo
Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
2026-11-05 13:00 · Yahoo
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
2026-09-03 12:00 · Yahoo
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
2026-08-13 12:00 · Yahoo
Grace Therapeutics Announces $10 Million Private Placement
2026-08-05 01:00 · Yahoo
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
2026-07-28 11:00 · Yahoo
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
2026-06-18 12:00 · Yahoo
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
2026-04-23 17:13 · Yahoo
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
2026-04-14 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.